Kazia Therapeutics (ASX:KZA) Share Price and News - StockTrack

Market Cap (15-Nov) $18,907,918 (738th)	Close (30-Jun) $0.160 0 (0%)	Volume (30-Jun) 68,980	Shortsold (1-Nov) 1 (0.00%) (657th)
52w High $0.000	52w Low $0.000	P/E -	EPS -0.11

	Subject
	KZA KZA Ann: GBM Agile opens to paxalisib in Canada
	1 (current) 2 3
	KZA KZA Ann: Notification of cessation of securities - KZA
	KZA KZA Ann: Notification regarding unquoted securities - KZA
	KZA KZA Ann: Kazia appoints John Friend as CMO
	KZA KZA Ann: Kazia enrols first patient to PNOC study
	KZA KZA Ann: Kazia AGM - Results of Meeting
	KZA KZA Ann: Chairman's Address to Shareholders
	KZA KZA Ann: Notification of cessation of securities - KZA
	KZA KZA Ann: Notification of cessation of securities - KZA
	KZA KZA Ann: Kazia enrols first patient to EVT801 Phase I clinical trial
	KZA KZA Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	KZA KZA Ann: Notice of General Meeting/Proxy Form
	KZA KZA Ann: Kazia AGM date
	KZA KZA Ann: Notification of cessation of securities - KZA
	KZA KZA Ann: Notification regarding unquoted securities - KZA
	KZA KZA Ann: Kazia's EVT801 phase I trial receives regulatory approval
	KZA KZA Ann: Shareholder information - amendment
	KZA KZA Ann: Change in Directors interests
	KZA KZA Ann: Kazia Annual Report to shareholders
	KZA KZA Ann: Kazia Corporate Governance Statement
	KZA KZA Ann: Kazia Appendix 4G
	KZA KZA Ann: Kazia Appendix 4E
	KZA KZA Ann: Kazia corporate presentation
	KZA KZA Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	KZA KZA Ann: Kazia update
	KZA KZA Ann: Manufacturing patents granted for paxalisib
	KZA KZA Ann: Ceasing to be a substantial holder
	KZA KZA Ann: Kazia launches new paxalisib phase II clinical trial
	KZA KZA Ann: Kazia paxilisib in Dana Farber study enrols first patient
	KZA KZA Ann: Appendix 3Y for 3 directors
	KZA KZA Ann: Change in substantial holding
	KZA KZA Ann: Appendix 2A
	KZA KZA Ann: Change in substantial holding
	KZA KZA Ann: Change of directors interests * 3
	KZA KZA Ann: Cleansing notice
	KZA KZA Ann: Appendix 4C - quarterly
	KZA KZA Ann: Appendix 2A
	KZA KZA Ann: Kazia Corporate Presentation
	KZA KZA Ann: Kazia licenses EVT801 from Evotec
	KZA KZA Ann: Trading Halt
	KZA KZA Ann: Kazia presents PK data for paxalisib at AACR meeting
	KZA KZA Ann: Change in substantial holding
	KZA KZA Ann: Change in substantial holding
	KZA KZA Ann: Proposed issue of Securities - KZA
	KZA KZA Ann: Proposed issue of Securities - KZA
	KZA KZA Ann: Kazia licenses paxalisib to Simcere in Greater China
	KZA KZA Ann: Trading Halt
	KZA KZA Ann: Kazia March Newsletter
	KZA KZA Ann: Appendix 2A
	KZA KZA Ann: Proposed issue of Securities - KZA

Similar Companies

CSL

Clinuvel Pharmaceuticals

CUV

Immutep

IMM

Imugene

IMU

Mesoblast

MSB

Opthea

OPT

Paradigm Biopharmaceuticals

PAR

PYC Therapeutics

PYC

Race Oncology

RAC

Telix Pharmaceuticals

TLX

End of Day Prices

Date	Close	Volume	Change
15-Nov	$0.08	0	0.00 (0.00%)
14-Nov	$0.08	0	0.00 (0.00%)
13-Nov	$0.08	454,181	+0.01 (9.59%)
10-Nov	$0.07	1,958,419	-0.01 (16.09%)
09-Nov	$0.09	2,428,685	-0.02 (20.91%)
08-Nov	$0.11	1,035,042	+0.03 (37.50%)
07-Nov	$0.08	489,091	+0.01 (19.40%)
06-Nov	$0.07	1,622,414	+0.01 (21.82%)
03-Nov	$0.06	938,181	0.00 (0.00%)
02-Nov	$0.06	1,610,003	-0.01 (9.84%)
01-Nov	$0.06	742,258	-0.01 (12.86%)
31-Oct	$0.07	1,267,882	-0.01 (12.50%)
30-Oct	$0.08	732,079	-0.01 (5.88%)
27-Oct	$0.09	596,210	0.00 (4.49%)
26-Oct	$0.09	399,238	0.00 (1.11%)
4 up, 8 down, and 3 flat days

High $0.16	Low $0.16	Trades 13	Turnover $11,013	Volume 68,980
30 June 2023 at 12:18pm

High $0.16	Low $0.16	Trades 13	Turnover $11,013	Volume 68,980
30 June 2023 at 12:18pm

Kazia Therapeutics Health Care
Cancer Medical

$0.160 -0.005 (-3.03%)

$0.160 -0.005 (-3.03%)

Followers

Prices

Announcements

Similar Companies

End of Day Prices

KZA Kazia Therapeutics Health Care Cancer Medical

$0.160 -0.005 (-3.03%)

$0.160 -0.005 (-3.03%)

Followers

Prices

Announcements

Similar Companies

End of Day Prices

Kazia Therapeutics Health Care
Cancer Medical